Laurak (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, a key regulator of neurotransmitter release. By modulating SV2A activity, the drug reduces excessive excitatory signaling in the brain, stabilising neuronal firing and decreasing the likelihood of seizure initiation and spread.

The dosage of Laurak is individualized by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. Physicians determine the appropriate starting dose and any subsequent titration to achieve optimal seizure control while minimising adverse effects.

Safety data for levetiracetam in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against possible risks and discuss alternative options. Women who are pregnant, planning pregnancy, or breastfeeding should consult their prescriber before starting or continuing Laurak.

To request Laurak, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with older agents such as carbamazepine or valproate, levetiracetam has a relatively favourable interaction profile and does not require routine therapeutic drug monitoring. It is often chosen for patients who need a medication with fewer enzyme‑inducing effects, though individual response and tolerability vary.

Laurak should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and excessive heat. Keep the product out of reach of children and avoid exposing it to direct sunlight or humid environments.

Laurak is taken orally, usually as a tablet or capsule, and should be swallowed whole with water. It can be taken with or without food, but consistency with meals helps maintain stable absorption. Follow the prescriber’s instructions regarding timing and any dose adjustments.

Serious adverse events include severe allergic reactions (anaphylaxis), life‑threatening skin conditions such as Stevens‑Johnson syndrome, significant mood changes including depression or suicidal thoughts, and rare blood disorders. Patients should seek immediate medical attention if they experience rash, mood disturbances, or signs of an allergic reaction.

Laurak is contraindicated in individuals with known hypersensitivity to levetiracetam or any of its excipients. Caution is advised for patients with severe renal impairment, uncontrolled psychiatric conditions, or those taking medications that markedly reduce levetiracetam levels without appropriate monitoring.